Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CART22 / University of Pennsylvania
NCT05674175: Co-administration of CART22-65s and huCART19 for B-ALL	Recruiting	1/2	93	US	Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), CART22-65s, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19), huCART19	Stephan Grupp MD PhD, University of Pennsylvania	B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma	01/27	01/29
NCT03620058: CART22 Alone or in Combination With huCART19 for ALL	Active, not recruiting	1	23	US	CART22-65s cells, huCART19 Cells	University of Pennsylvania	Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia	01/36	01/36
NCT02650414: CD22 Redirected Autologous T Cells for ALL	Recruiting	1	15	US	CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB	University of Pennsylvania, Children's Hospital of Philadelphia	B Cell Leukemias, B Cell Lymphomas	12/37	12/37